-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 19, Biotech issued an announcement stating that the company had recently received the "Clinical Trial Approval Notice" for the company's drug BAT7104 injection, which was approved and issued by the National Medical Products Administration
.
BAT7104 is a bispecific antibody against PD-L1 and CD47 developed by Biotech, which is intended to be developed for tumor treatment
.
BAT7104 activates macrophages to phagocytose tumor cells by blocking the CD47/SIRPα pathway; BAT7104 blocks the PD-L1/PD-1 pathway to relieve tumor cells from inhibiting T cells through the PD-L1/PD-1 pathway, and achieve T The combined anti-tumor effect of cells and macrophages